Health Care [ 8/12 ] | Pharmaceuticals [ 50/74 ]
NASDAQ | Common Stock
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection.
In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development.
The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir.
Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 26 | -0.57 Decreased by -43.45% | -0.56 Decreased by -3.39% |
| Mar 5, 26 | -0.57 Decreased by -42.50% | -0.48 Decreased by -18.75% |
| Nov 12, 25 | -0.53 Decreased by -43.24% | -0.41 Decreased by -29.27% |
| Aug 7, 25 | -0.44 Increased by +8.33% | -0.45 Increased by +2.22% |
| May 12, 25 | -0.40 Increased by +46.67% | -0.41 Increased by +2.44% |
| Feb 26, 25 | -0.40 Increased by +14.89% | -0.29 Decreased by -38.12% |
| Nov 7, 24 | -0.37 Increased by +7.50% | -0.43 Increased by +13.95% |
| Aug 7, 24 | -0.48 Decreased by -41.18% | -0.77 Increased by +37.66% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 0.00 Decreased by N/A% | -45.44 M Decreased by -32.59% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 25 | 0.00 Decreased by -100.00% | -44.87 M Decreased by -33.76% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -42.05 M Decreased by -34.98% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -37.16 M Increased by +8.29% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -34.27 M Increased by +45.75% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 416.00 K Increased by +N/A% | -33.54 M Increased by +14.35% | Decreased by -8.06 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -31.15 M Increased by +6.01% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -40.52 M Decreased by -43.78% | Decreased by N/A% Decreased by N/A% |